Urogen Pharma

$17.02 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest

Subscribe

About Urogen Pharma

UroGen Pharma Ltd. Is an Israel-based biopharmaceutical company. The Company is engaged in building solutions for cancers and urologic diseases. UroGen has developed RTGelTM reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. Its lead product candidates include MitoGel and VesiGel are formulated using its proprietary reverse thermally triggered hydrogel, or RTGel, technology. MiroGel ( UGN-101) is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract. VesiGel (UGN-102) is a sustained release formulation of a high dose Mitomycin C for the treatment of low grade non-muscle invasive bladder cancer (LG-NMIBC).

Stock Analysis

last close $17.02
1-mo return 11.8%
3-mo return 10.5%
avg daily vol. 52.97T
52-week high 28.2
52-week low 14.19
market cap. $355M
forward pe -
annual div. -
roe -112.1%
ltg forecast -
dividend yield -
annual rev. $32M
inst own. 76.2%
baraka

Subscribe now for daily local and international financial news

Subscribe